Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 2.0 mg injection once weekly
DULA_SC_2p0MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.58 (0.01 to 46.04) | 0.45 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.61 (0.05 to 4.63) | 0.62 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.25 (0.76 to 6.78) | 0.55 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.79 (0.75 to 11.05) | 0.48 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.73 (0.61 to 4.96) | 0.47 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.33 (0.78 to 13.87) | 0.26 |